Constantly, the human Skin is exposed to various microbes, viruses, pollutants, UV/other radiation and other
stressors that exist in day today life. Eventually, our skin is most commonly encountered with infectious and noninfectious
skin diseases such as psoriasis, acne, vitiligo, eczema, acrodermatitis, cutaneous candidiasis, athelete’s
foot, cutaneous leishmaniasis and rosacea, skin cancer, etc [1-5]. To date, it is well established that topical medication
in skin diseases is more effective and has lesser side effects than systemic application. Yet, physicochemical
properties of drugs and skin anatomy particularly the stratum corneum are the major barriers in effective topical
pharmacotherapy [6-8]. Exploiting the fact that beneath the stratum corneum, epidermis of the skin is composed
lipids and lipoproteins, nanomedicines of lipophilic surface as a topical drug carrier are currently being developed
and seems very promising at clinical stage [6-8]. In recent decades, many liposomes, nanoemulsion gels and lipid
nanoparticles have been approved for the medication of infectious and non-infectious skin conditions. Many more
from the diverse serious of lipidic and polymeric nanoparticles are currently being investigated at the preclinical
level intended for improving the low penetration of active agents into the skin, which limits not only the topical
therapy of skin disease but also transdermal therapy [9, 10].
This thematic issue presents a concise yet very focused on-going research on topical infective and non-infective
diseases, available medications and its associated challenges in their treatment. Moreover, the implantation of nanodrug
discovery for topical medication in infective and non-infective skin diseases has been introduced to overcome
the problems associated with conventional topical formulations. Furthermore, In this issue, up-to-date, broadly and
interdisciplinary discussed reviews on topical nano-drug discovery will help the pharmaceutical, biomedical researchers
and dermatologists in understanding the challenges of topical drug delivery, and how with the nanomedicines
strategy, we can improve our therapy. But still lack of sufficient evidence in a clinical setup is a constraint
and more clinical studies on the efficacy and safety of nanomedicines in skin therapy are required.